Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 10, 2014 13:34 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics Presents New Data for DALVANCE(TM) at IDWeek 2014(TM)

CHICAGO, Oct. 10, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced a summary of presentation data from its recently launched product, DALVANCE™ (dalbavancin) for...
October 03, 2014 08:00 ET | Source: Durata Therapeutics, Inc.

FDA Grants Durata Therapeutics a Special Protocol Agreement (SPA) for Its Phase 3 Study of DALVANCE(TM) in Hospitalized Community-Acquired Pneumonia

CHICAGO, Oct. 3, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that the Company has received a Special Protocol Agreement (SPA) from the Food and Drug Administration (FDA)...
October 02, 2014 09:00 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Present Five Posters at IDWeek 2014

CHICAGO, Oct. 2, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that it will present five posters highlighting data from its recently launched product, DALVANCE™...
September 09, 2014 09:00 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics Presented Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

CHICAGO, Sept. 9, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from its recently launched product, DALVANCE™ (dalbavancin) for injection, was...
September 03, 2014 09:00 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Present Safety and Efficacy Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

CHICAGO, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that that it will present seven posters highlighting safety and efficacy data from its recently launched...
August 26, 2014 17:00 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics Names Wendy Yarno and J. Martin Carroll to Its Board of Directors

CHICAGO, Aug. 26, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that Wendy Yarno and Marty Carroll were added to its Board of Directors at a quarterly meeting of the Board...
August 07, 2014 07:00 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics Reports Second Quarter 2014 Financial Results

CHICAGO, Aug. 7, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced financial results for the quarter ended June 30, 2014. "This was a very busy and exciting quarter...
August 06, 2014 08:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Present at Upcoming Investor Conference

CHICAGO, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, Chief Executive Officer, will present at the Wedbush 2014 Life Sciences Management...
July 31, 2014 08:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Report Second Quarter 2014 Financial Results on August 7, 2014

CHICAGO, July 31, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) has scheduled its quarterly conference call for Thursday, August 7 at 8:30 a.m. Eastern Time to discuss second...
July 30, 2014 08:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics Enters Into an Exclusive License and Supply Agreement With Angelini to Commercialize Dalbavancin in Certain European Territories, Russia and Turkey

CHICAGO, July 30, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) announced today that its Dutch subsidiary, Durata Therapeutics International B.V., has entered into a license and...